company background image
CDXC

ChromaDexNasdaqCM:CDXC Stock Report

Last Price

US$2.76

Market Cap

US$188.7m

7D

-8.3%

1Y

-43.7%

Updated

21 Jan, 2022

Data

Company Financials +
CDXC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CDXC Stock Overview

ChromaDex Corporation operates as a bioscience company focusing on healthy aging.

ChromaDex Competitors

BASF

XTRA:BAS

€60.7b

Lonza Group

SWX:LONN

CHF47.7b

Koninklijke DSM

ENXTAM:DSM

€29.9b

Eurofins Scientific

ENXTPA:ERF

€17.2b

Price History & Performance

Summary of all time highs, changes and price drops for ChromaDex
Historical stock prices
Current Share PriceUS$2.76
52 Week HighUS$23.66
52 Week LowUS$2.72
Beta1.64
1 Month Change-32.85%
3 Month Change-56.74%
1 Year Change-43.67%
3 Year Change-18.34%
5 Year Change-4.83%
Change since IPO-75.47%

Recent News & Updates

Nov 19
Companies Like ChromaDex (NASDAQ:CDXC) Can Afford To Invest In Growth

Companies Like ChromaDex (NASDAQ:CDXC) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Sep 14
When Should You Buy ChromaDex Corporation (NASDAQ:CDXC)?

When Should You Buy ChromaDex Corporation (NASDAQ:CDXC)?

ChromaDex Corporation ( NASDAQ:CDXC ), might not be a large cap stock, but it saw significant share price movement...

Shareholder Returns

CDXCUS Life SciencesUS Market
7D-8.3%-4.7%-6.1%
1Y-43.7%1.8%4.2%

Return vs Industry: CDXC underperformed the US Life Sciences industry which returned 4.2% over the past year.

Return vs Market: CDXC underperformed the US Market which returned 6.6% over the past year.

Price Volatility

Is CDXC's price volatile compared to industry and market?
CDXC volatility
CDXC Average Weekly Movement7.0%
Life Sciences Industry Average Movement9.1%
Market Average Movement6.7%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.4%

Stable Share Price: CDXC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CDXC's weekly volatility has decreased from 17% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a110Rob Friedhttps://www.chromadex.com

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

ChromaDex Fundamentals Summary

How do ChromaDex's earnings and revenue compare to its market cap?
CDXC fundamental statistics
Market CapUS$188.74m
Earnings (TTM)-US$27.90m
Revenue (TTM)US$65.14m

2.9x

P/S Ratio

-6.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CDXC income statement (TTM)
RevenueUS$65.14m
Cost of RevenueUS$25.09m
Gross ProfitUS$40.04m
ExpensesUS$67.94m
Earnings-US$27.90m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.41
Gross Margin61.48%
Net Profit Margin-42.83%
Debt/Equity Ratio0%

How did CDXC perform over the long term?

See historical performance and comparison

Valuation

Is ChromaDex undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CDXC ($2.76) is trading below our estimate of fair value ($69.26)

Significantly Below Fair Value: CDXC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CDXC is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: CDXC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CDXC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CDXC is overvalued based on its PB Ratio (5.3x) compared to the US Life Sciences industry average (3.2x).


Future Growth

How is ChromaDex forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

77.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CDXC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: CDXC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CDXC's is expected to become profitable in the next 3 years.

Revenue vs Market: CDXC's revenue (26.6% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: CDXC's revenue (26.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CDXC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has ChromaDex performed over the past 5 years?

-18.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CDXC is currently unprofitable.

Growing Profit Margin: CDXC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CDXC is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.

Accelerating Growth: Unable to compare CDXC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CDXC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (72.2%).


Return on Equity

High ROE: CDXC has a negative Return on Equity (-78.7%), as it is currently unprofitable.


Financial Health

How is ChromaDex's financial position?


Financial Position Analysis

Short Term Liabilities: CDXC's short term assets ($52.8M) exceed its short term liabilities ($17.8M).

Long Term Liabilities: CDXC's short term assets ($52.8M) exceed its long term liabilities ($7.2M).


Debt to Equity History and Analysis

Debt Level: CDXC is debt free.

Reducing Debt: CDXC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CDXC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CDXC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is ChromaDex current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CDXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CDXC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CDXC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CDXC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CDXC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Rob Fried (61 yo)

3.58yrs

Tenure

US$1,126,685

Compensation

Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of ChromaDex Corp. since June 22, 2018 and its a Director since July 2015. Mr. Fried was the Chief Operating Officer of ChromaDe...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD1.13M) is about average for companies of similar size in the US market ($USD1.13M).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CDXC's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: CDXC's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.


Top Shareholders

Company Information

ChromaDex Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: ChromaDex Corporation
  • Ticker: CDXC
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$188.738m
  • Shares outstanding: 68.38m
  • Website: https://www.chromadex.com

Number of Employees


Location

  • ChromaDex Corporation
  • 10900 Wilshire Boulevard
  • Suite 600
  • Los Angeles
  • California
  • 90024
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 23:45
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.